MedTrace Logo

Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma

NCT05994170 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 454

Last updated 2023-08-16

No results posted yet for this study

Summary

To evaluate the long-term local control, survival rate, acute and late radiation related toxicities, quality of life after reducing high risk primary tumor clinical target volumes (CTVp1) in non-metastatic nasopharyngeal carcinoma treated with IMRT.

Conditions

  • Nasopharyngeal Carcinoma
  • Intensity-Modulated Radiotherapy

Interventions

RADIATION

Reduction CTVp1

High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as 5mm margin from GTVp,including pre-induction chemotherapy tumor extension( CTVp1=GTVp+5mm)

RADIATION

Non-reduction CTVp1

High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as whole nasopharynx as well as 5mm margin from GTVp( CTVp1=GTVp+5mm+whole nasopharynx)

Sponsors & Collaborators

  • Sun Yat-sen University Cancer Centre

    collaborator UNKNOWN

  • Zhongshan People's Hospital, Guangdong, China

    lead OTHER

Principal Investigators

  • Gui-qiong Xu · Zhongshan People's Hospital, Guangdong, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-04
Primary Completion
2026-08-04
Completion
2029-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05994170 on ClinicalTrials.gov